In conclusion, we suggest that the anti-tumor drug that target the TUBB/Rho/ROCK signaling pathway may be co-treated with oral antibiotics targeting E. coli, which may activate T cells, strengthen immune protection, boost immune surveillance, and enhance sensitivity to immunotherapy in PC. The gene discussed is RHO; the disease is neoplasm.